Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LIXT NASDAQ:MCRB NASDAQ:MDCX NASDAQ:XBIT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIXTLixte Biotechnology$7.00$4.43$0.64▼$7.50$86.68M1.27157,907 shs149,780 shsMCRBSeres Therapeutics$6.63-3.2%$8.08$6.32▼$29.98$66.33M0.1335,847 shs280,863 shsMDCXMedicus Pharma$0.35-6.3%$0.35$0.25▼$3.69$21.17M0.142.49 million shs1.69 million shsXBITXBiotech$2.37$2.43$2.09▼$3.61$72.26M0.8528,487 shs33,188 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIXTLixte Biotechnology+4.32%+16.86%+55.90%+186.89%+403.60%MCRBSeres Therapeutics-4.46%-9.63%-8.67%-24.97%-3.93%MDCXMedicus Pharma+4.47%+13.45%+35.85%-3.54%-86.41%XBITXBiotech-0.84%-2.87%-7.06%+0.85%-19.39%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIXTLixte Biotechnology$7.00$4.43$0.64▼$7.50$86.68M1.27157,907 shs149,780 shsMCRBSeres Therapeutics$6.63-3.2%$8.08$6.32▼$29.98$66.33M0.1335,847 shs280,863 shsMDCXMedicus Pharma$0.35-6.3%$0.35$0.25▼$3.69$21.17M0.142.49 million shs1.69 million shsXBITXBiotech$2.37$2.43$2.09▼$3.61$72.26M0.8528,487 shs33,188 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIXTLixte Biotechnology+4.32%+16.86%+55.90%+186.89%+403.60%MCRBSeres Therapeutics-4.46%-9.63%-8.67%-24.97%-3.93%MDCXMedicus Pharma+4.47%+13.45%+35.85%-3.54%-86.41%XBITXBiotech-0.84%-2.87%-7.06%+0.85%-19.39%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLIXTLixte Biotechnology 1.00SellN/AN/AMCRBSeres Therapeutics 2.00Hold$22.00231.83% UpsideMDCXMedicus Pharma 2.25Hold$9.002,471.43% UpsideXBITXBiotech 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest MDCX, XBIT, LIXT, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/26/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/18/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/12/2026LIXTLixte Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026XBITXBiotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026XBITXBiotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026MDCXMedicus Pharma Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy4/20/2026MDCXMedicus Pharma D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.004/10/2026MDCXMedicus Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/27/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/19/2026MDCXMedicus Pharma D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$27.003/13/2026MCRBSeres Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.00(Data available from 6/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLIXTLixte BiotechnologyN/AN/AN/AN/A$1.05 per shareN/AMCRBSeres Therapeutics$1.15M55.98$1.00 per share6.60$4.89 per share1.36MDCXMedicus PharmaN/AN/AN/AN/AN/AN/AXBITXBiotechN/AN/AN/AN/A$4.60 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLIXTLixte Biotechnology-$6.01M-$1.13N/AN/AN/AN/A-134.91%-95.61%N/AMCRBSeres Therapeutics$5.70M-$5.17N/AN/AN/AN/A-130.29%-35.35%8/5/2026 (Estimated)MDCXMedicus Pharma-$35.46M-$2.68N/AN/AN/AN/A-3,137.84%-311.33%8/10/2026 (Estimated)XBITXBiotech-$45.54M-$1.32N/AN/AN/AN/A-26.10%-25.06%N/ALatest MDCX, XBIT, LIXT, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026LIXTLixte BiotechnologyN/A-$0.18N/A-$0.18N/AN/A5/14/2026Q1 2026MDCXMedicus Pharma-$0.18-$0.31-$0.13-$0.31N/AN/A5/14/2026Q1 2026XBITXBiotech$0.03-$0.18-$0.21-$0.18$7.00 millionN/A5/5/2026Q1 2026MCRBSeres Therapeutics-$1.88-$2.08-$0.20-$2.08$0.36 million$0.36 million3/26/2026Q4 2025MDCXMedicus Pharma-$0.32-$0.82-$0.50-$0.83N/AN/A3/13/2026Q4 2025XBITXBiotechN/A-$0.88N/A-$0.88N/AN/A3/12/2026Status updateMCRBSeres Therapeutics-$2.39-$1.89+$0.50-$1.76N/A$0.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthLIXTLixte BiotechnologyN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/AMDCXMedicus PharmaN/AN/AN/AN/AN/AXBITXBiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLIXTLixte BiotechnologyN/A2.782.78MCRBSeres TherapeuticsN/A1.651.65MDCXMedicus PharmaN/A1.221.22XBITXBiotechN/A39.0339.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLIXTLixte Biotechnology5.10%MCRBSeres Therapeutics59.34%MDCXMedicus PharmaN/AXBITXBiotech55.70%Insider OwnershipCompanyInsider OwnershipLIXTLixte Biotechnology9.50%MCRBSeres Therapeutics5.20%MDCXMedicus Pharma8.10%XBITXBiotech30.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLIXTLixte Biotechnology412.38 million11.21 millionNot OptionableMCRBSeres Therapeutics3309.68 million9.18 millionOptionableMDCXMedicus PharmaN/A56.66 million52.07 millionN/AXBITXBiotech10030.49 million21.10 millionOptionableMDCX, XBIT, LIXT, and MCRB HeadlinesRecent News About These CompaniesXBiotech (NASDAQ:XBIT) Stock Price Crosses Below 50 Day Moving Average - Time to Sell?May 30, 2026 | americanbankingnews.comXBiotech’s New Axial Spondyloarthritis Trial Puts Vilamakitug on Investors’ RadarMay 14, 2026 | tipranks.comXBiotech: Q4 Earnings SnapshotMarch 13, 2026 | chron.comXBiotech’s New Trial: A Potential Game-Changer for Rheumatoid Arthritis Treatment?October 28, 2025 | msn.comXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insidersAugust 28, 2025 | finance.yahoo.comThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationMarch 2, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmMarch 1, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 28, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 27, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 26, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 25, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 24, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 23, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 22, 2025 | accessnewswire.comAAn Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 21, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 20, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 18, 2025 | accessnewswire.comAXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 17, 2025 | accessnewswire.comAThe Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud InvestigationFebruary 16, 2025 | accessnewswire.comAXBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law FirmFebruary 15, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDCX, XBIT, LIXT, and MCRB Company DescriptionsLixte Biotechnology NASDAQ:LIXT$7.00 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$6.89 -0.11 (-1.57%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.Seres Therapeutics NASDAQ:MCRB$6.63 -0.22 (-3.21%) Closing price 04:00 PM EasternExtended Trading$6.48 -0.15 (-2.26%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Medicus Pharma NASDAQ:MDCX$0.35 -0.02 (-6.32%) Closing price 04:00 PM EasternExtended Trading$0.35 0.00 (0.00%) As of 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Medicus Pharma Ltd is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets. Medicus Pharma Ltd is based in Toronto, Ontario.XBiotech NASDAQ:XBIT$2.37 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$2.37 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? Buy the Dip? Broadcom's AI Moat Is Wider Than Ever The Market Has Ollie’s Bargain Outlet Completely Wrong Broadcom's Whiplash: Shares Tank After Pre-Earnings Surge Navitas: NVIDIA’s AI Power Broker? Macy's Delivers Strong Q1, Raises Outlook, but Wall Street Remains Cautious NVIDIA's New Power Play: Why Fluence Is Surging Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
